1. Psoriasis

Category Archives: Psoriasis

WHY has coal tar shampoo, standby for psoriasis and eczema disappeared?

Posted on by

By Erin Dean

PUBLISHED: 20:42 EST, 3 March 2014 | UPDATED: 05:54 EST, 4 March 2014

374 shares

533

View comments

Polytar Plus shampoo, 8.99

For decades, Ray Jobling has used a special medicated shampoo to help control his psoriasis. The condition is caused by overproduction of skin cells, leading to a build-up of itchy and sore patches of skin.

Psoriasis can appear anywhere on the body, but is most common on the scalp, elbows, knees and lower back.

Ray, a 72-year-old retired Cambridge University academic, has psoriasis on his scalp and has long relied on Polytar, a shampoo made with coal tar, a by-product of the industrial process that turns coal into coke.

Coal-tar shampoo, an over-the-counter product, has been a standby for psoriasis and other skin conditions, including eczema and cradle cap, for years.

Follow this link:

WHY has coal tar shampoo, standby for psoriasis and eczema disappeared?

Coal tar shampoo was a standby for psoriasis and eczema. So why HAS this trusted skin treatment disappeared?

Posted on by

By Erin Dean

PUBLISHED: 20:42 EST, 3 March 2014 | UPDATED: 20:42 EST, 3 March 2014

Polytar Plus shampoo, 8.99

For decades, Ray Jobling has used a special medicated shampoo to help control his psoriasis. The condition is caused by overproduction of skin cells, leading to a build-up of itchy and sore patches of skin.

Psoriasis can appear anywhere on the body, but is most common on the scalp, elbows, knees and lower back.

Ray, a 72-year-old retired Cambridge University academic, has psoriasis on his scalp and has long relied on Polytar, a shampoo made with coal tar, a by-product of the industrial process that turns coal into coke.

Coal-tar shampoo, an over-the-counter product, has been a standby for psoriasis and other skin conditions, including eczema and cradle cap, for years.

But 18 months ago, it suddenly started disappearing from chemists' shelves for reasons that are far from clear.

Ray's doctor suggested he try Carbo Dome, a coal tar cream - but then a year ago this, too, started to vanish.

Ray, who was diagnosed with psoriasis when he was 14, says for those with painful skin conditions, losing a product that has been relied on for years can have a big impact (2 per cent of the population has psoriasis).

Read the rest here:

Coal tar shampoo was a standby for psoriasis and eczema. So why HAS this trusted skin treatment disappeared?

Case of Psoriasis showing relapse of Psoriasis after stopping Methotrexate and Cortisone – Video

Posted on by


Case of Psoriasis showing relapse of Psoriasis after stopping Methotrexate and Cortisone
(48) Case of Psoriasis showing relapse of Psoriasis after stopping Methotrexate and Cortisone. More information on this topic at http://www.askdrshah.com/app...

By: lifeforcehomeopathy

Read this article:

Case of Psoriasis showing relapse of Psoriasis after stopping Methotrexate and Cortisone - Video

A case of Psoriasis showing flare up after using and stopping Cortisone and Propysalic acid cream – Video

Posted on by


A case of Psoriasis showing flare up after using and stopping Cortisone and Propysalic acid cream
(67) A case of Psoriasis showing flare up after using and stopping Cortisone and Propysalic acid cream, documented at Life Force. We have observed in hundred...

By: lifeforcehomeopathy

See the article here:

A case of Psoriasis showing flare up after using and stopping Cortisone and Propysalic acid cream - Video

Stacy London leads Uncover Your Confidence psoriasis campaign

Posted on by

NEW YORK, Feb. 28 (UPI) -- New York style guru Stacy London says her work on the "Uncover Your Confidence" psoriasis campaign supports her mission of helping people look and feel their best.

A former Vogue fashion editor and the author of the book "The Truth About Style," London was the co-host of the makeover show "What Not to Wear" for 10 seasons before the series concluded on TLC last fall. She also has psoriasis herself and is happy to advise people dealing with the immune-mediated skin disease through UncoverYourConfidence.com, a website set up by AbbVie, a research-based pharmaceuticals company.

"AbbVie approached me after my book came out. I talked a little bit about having psoriasis on 'What Not to Wear,' but not extensively. But I did talk a lot about it in the book and, certainly, as a kid, it's not like I was filled with confidence, and, so, it really has been this kind of perfect storm for me -- to [not only] be able to talk about my personal experience, but to be able to put my skill set into this particular campaign, which is about empowerment and, certainly, about patient advocacy," London told United Press International in a recent phone interview.

She went on to say she wants people with the skin condition to know "psoriasis is just a part of you, like your height or your weight or your eye color and you can either work with it or against it.

"If you work with it, chances are you're going to look better and feel better and be able to accept yourself more wholly," London said. "It's not about hiding. I think that goes for style in general. If you don't like something about yourself, you don't hide it because hiding already implies shame. It's about conscientious camouflage in a way that you feel like you're putting your strengths forward and whatever you think are your weaknesses, you are just conscientiously camouflaging. That [feature is] not what you lead with."

Organizers of the campaign said it aims to provide people living with psoriasis with resources, support and style information to encourage them to take a proactive approach to their condition.

The rest is here:

Stacy London leads Uncover Your Confidence psoriasis campaign

CNIO researchers discover new strategies for the treatment of psoriasis

Posted on by

PUBLIC RELEASE DATE:

27-Feb-2014

Contact: Nuria Noriega nnoriega@cnio.es Centro Nacional de Investigaciones Oncologicas (CNIO)

Almost ten years ago, the group led by Erwin Wagner, currently at the Spanish National Cancer Research Centre (CNIO), developed genetically modified mice showing symptoms very reminiscent to psoriasis. After publishing this discovery in Nature, the researchers decided to use this mouse model to study the underlying molecular pathways involved in disease development, and to look for innovative and efficient therapies. Now the group has discovered two possible novel treatments, based on existing pharmacological compounds, which are likely to cause fewer side effects.

Psoriasis affects up to 3% of the world's population and can seriously affect the quality of life of these patients. The primary causes are largely unknown and the disease is not curable. The latest generation of drugs developed to combat it - so-called biological therapies - are thought to be a big step forward, but can only be applied for limited periods of time due to serious side effects, which can generate other forms of psoriasis, or even cause tuberculosis or leukaemia. Due to this it is important for psoriatic patients to develop efficient non-toxic treatments.

The two new strategies now published by CNIO researchers are the result of in-depth studies of the disease biology that have revealed some of the underlying molecular causes.

In the first study published in the December issue of the high impact journal Immunity, it is shown how the symptoms of psoriasis disappear by deleting a protein called S100A9. In the second article, which is published in Science Translational Medicine, the researchers show that inhibiting a non-coding micro RNA, named miR-21, ameliorates the disease symptoms.

As Helia Schnthaler, the first author, and collegues write in Immunity: "over the past decade, biological therapies have been shown to be effective against inflammatory diseases. These treatments, however, are a cause of worry due to their side effects, which might cause a possible increase in the risk of infection or cancer. The development of efficient, locally applicable drugs without these side effects, therefore would be beneficial for patients with psoriasis". Specifically, S100A9 inhibiting strategies "have the potential to become effective new treatments against psoriasis", the authors state.

In the article in Science Translational Medicine, which features Juan Guinea-Viniegra as the lead author, the authors state that: "blocking miR-21 could offer advantages over current treatments given that the efficiency obtained is the same and the side effects are probably reduced". The authors highlight that in the mouse model and in patient samples transplanted into mice this new strategy "shows a significant therapeutic response".

Helia Schnthaler and Juan Guinea-Viniegra are members of the group of Erwin Wagner, who is the director of the F-BBVA-CNIO Cancer Cell Biology Programme.

More:

CNIO researchers discover new strategies for the treatment of psoriasis


  1. Psoriasis